(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.7%.
Longeveron's earnings in 2024 is -$27,904,000.On average, 2 Wall Street analysts forecast LGVN's earnings for 2024 to be -$55,930,167, with the lowest LGVN earnings forecast at -$64,186,867, and the highest LGVN earnings forecast at -$47,673,467.
In 2025, LGVN is forecast to generate -$26,349,642 in earnings, with the lowest earnings forecast at -$34,462,747 and the highest earnings forecast at -$18,236,537.